| Literature DB >> 31072079 |
Junghoon Yu1, Youngsu Jung1, Joonhyun Park1, Jong Moon Kim1,2, Miri Suh1,2, Kyung Gi Cho3, MinYoung Kim1,2.
Abstract
OBJECTIVE: To evaluate the effectiveness of intensive rehabilitation to support recovery of neurological function after brain tumor surgery and assess long-term satisfaction.Entities:
Keywords: Brain neoplasms; Neurological rehabilitation; Satisfaction; Treatment outcome
Year: 2019 PMID: 31072079 PMCID: PMC6509576 DOI: 10.5535/arm.2019.43.2.129
Source DB: PubMed Journal: Ann Rehabil Med ISSN: 2234-0645
Fig. 1.Recruitment flowchart detailing the number of participants included and excluded. WHO, World Health Organization.
Demographic and disease-related characteristics
| Brain tumor group (n=35) | Stroke group (n=108) | p-value | |
|---|---|---|---|
| Age (yr) | 57.6±13.2 | 60.9±11.6 | 0.275 |
| Gender | 0.890 | ||
| Male | 18 (51.4) | 57 (52.8) | |
| Female | 17 (48.6) | 51 (47.2) | |
| Lesion location | 0.527 | ||
| Right hemisphere | 16 (45.7) | 47 (43.5) | |
| Left hemisphere | 14 (40.0) | 41 (38.0) | |
| Cerebellum | 2 (5.7) | 9 (8.3) | |
| Brain stem | 3 (8.6) | 11(10.2) | |
| Tumor etiology (WHO grade) | |||
| I (benign tumor) | 11 (31.4) | NA | - |
| II (benign tumor) | 10 (28.6) | ||
| III (malignant tumor) | 4 (11.4) | ||
| IV (malignant tumor) | 10 (28.6) | ||
| Recurrence | |||
| Primary | 24 (31.4) | ||
| Recurrent | 11 (68.6) | ||
| Length of rehabilitation (day) | 37.2±11.9 | 36.4±6.7 | 0.759 |
Values are presented as number or mean±standard deviation or number of patients (%).
Mean value and the percentage of each groups were compared by independent t-test.
Continuous data were tested by independent t-test and categorical data were tested by chi-square test.
WHO, World Health Organization; NA, not applicable.
Brain tumor characteristics
| Benign brain tumor (n=21) | Malignant brain tumor (n=14) | p-value | |
|---|---|---|---|
| Lesion location | 0.537 | ||
| Right frontal | 4 (19.0) | 3 (21.4) | |
| Right temporal | 2 (9.5) | 2 (14.3) | |
| Right parietal | 0 (0) | 1 (7.1) | |
| Right hypothalamus | 1 (4.8) | 0 (0) | |
| Right thalamus | 0 (0.0) | 1 (7.1) | |
| Left frontal | 1 (4.8) | 1 (7.1) | |
| Left temporal | 4 (19.0) | 2 (14.3) | |
| Left parietal | 1 (4.8) | 1 (7.1) | |
| Left thalamus | 0 (0) | 1 (7.1) | |
| Left cingulate gyrus | 0 (0) | 1 (7.1) | |
| Left lateral ventricle | 3 (14.3) | 0 (0.0) | |
| Cerebellum | 1 (4.8) | 1 (7.1) | |
| Brain stem | 3 (14.3) | 0 (0) | |
| Skull base | 1 (4.8) | 0 (0) | |
| Lesion size, long axis (cm) | 0.537 | ||
| 2–3 | 3(14.3) | 2 (14.3) | |
| 3–4 | 7 (33.3) | 4 (28.6) | |
| 4–5 | 6 (28.6) | 2 (14.3) | |
| 5–6 | 4 (19.0) | 3 (21.4) | |
| 6–7 | 1 (4.8) | 3 (21.4) | |
| Treatment modality | <0.001[ | ||
| Surgery | 13 (61.9) | 0 (0) | |
| Surgery+chemotherapy | 1 (4.8) | 2 (14.3) | |
| Surgery+radiotherapy | 7 (33.3) | 4 (28.6) | |
| Surgery+chemotherapy+radiotherapy | 0 (0) | 8 (57.1) | |
| Recurrence | |||
| Primary | 16 (76.2) | 8 (57.1) | <0.001[ |
| Recurrent | 5 (23.8) | 6 (42.9) | |
| Initial ECOG scale | |||
| 1 | 2 (9.5) | 0 (0) | 0.071 |
| 2 | 4 (19.0) | 3 (14.3) | |
| 3 | 7 (33.3) | 9 (42.9) | |
| 4 | 8 (38.1) | 2 (9.5) |
Values are presented as number of patients (%).
Benign brain tumor subgroup included atypical meningioma, atypical neurocytoma, chordoid glioma, chordoma, craniopharyngioma, hemangioblastoma, meningothelial meningioma, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, reactive gliosis and schwannoma. Malignant brain tumor subgroup included anaplastic astrocytoma and glioblastoma.
ECOG, Eastern Cooperative Oncology Group.
p<0.001, when continuous data were tested by independent t-test, and categorical data were tested by chi-square test.
Rehabilitation outcomes for brain tumor and stroke groups
| Brain tumor group (n=35) | Stroke group (n=108) | p-value[ | |||||
|---|---|---|---|---|---|---|---|
| Baseline | Discharge | p-value (within groups) | Baseline | Discharge | p-value (within groups) | ||
| FMA score | 34.5±22.2 | 49.1±17.5 | <0.001[ | 30.1±21.6 | 41.8±21.0 | <0.001[ | 0.737 |
| BBS score | 17.0±15.9 | 35.6±17.7 | <0.001[ | 20.7±18.0 | 35.2±17.7 | <0.001[ | 0.929 |
| K-MBI score | 36.9±18.5 | 58.3±20.1 | <0.001[ | 38.6±21.0 | 56.7±23.2 | <0.001[ | 0.447 |
| K-MMSE score | 17.3±10.1 | 23.1±7.6 | <0.001[ | 16.7±8.2 | 21.1±7.1 | <0.001[ | 0.569 |
| IQ score | 67.1±18.1 | 78.9±14.8 | <0.001[ | 69.6±18.4 | 78.5±18.4 | <0.001[ | 0.180 |
Values are presented as mean±standard deviation.
FMA, Fugl-Meyer Assessment; BBS, Berg Balance Scale; K-MBI, Korean version of Modified Barthel Index; K-MMSE, Korean Mini-Mental State Examination; IQ, intelligence quotient.
Compared difference of each score (score at discharge – score at admission) between two groups (brain tumor vs. stroke) by Mann-Whitney U test.
p<0.001 when comparing each scores of baseline and discharge within same group by Wilcoxon-signed rank test.
Rehabilitation outcomes for benign and malignant brain tumor subgroups
| Benign brain tumor (n=21) | Malignant brain tumor (n=14) | p-value[ | |||||
|---|---|---|---|---|---|---|---|
| Baseline | Discharge | p-value (within groups) | Baseline | Discharge | p-value (within groups) | ||
| FMA score | 36.7±22.3 | 51.1±15.4 | <0.001[ | 31.1±20.8 | 45.9±20.7 | 0.002[ | 0.434 |
| BBS score | 19.1±17.1 | 38.0±15.7 | <0.001[ | 13.9±13.0 | 32.1±20.1 | 0.002[ | 0.210 |
| K-MBI score | 37.7±20.2 | 61.4±21.6 | <0.001[ | 35.9±15.6 | 53.8±18.4 | 0.016[ | 0.702 |
| K-MMSE score | 15.5±7.3 | 23.5±5.1 | <0.001[ | 19.3±9.8 | 22.6±7.1 | <0.001[ | 0.220 |
| IQ score | 63.9±16.1 | 79.1±12.8 | 0.001[ | 71.5±20.7 | 78.5±17.7 | 0.002[ | 0.156 |
| ECOG scale | 3.0±0.8 | 2.9±0.4 | <0.001[ | 1.86±0.7 | 2.1±0.7 | 0.011[ | 0.175 |
Values are presented as mean±standard deviation.
FMA, Fugl-Meyer Assessment; BBS, Berg Balance Scale; K-MBI, Korean version of Modified Barthel Index; K-MMSE, Korean Mini-Mental State Examination; IQ, intelligence quotient; ECOG, Eastern Cooperative Oncology Group.
Compared difference of each score (score at discharge – score at admission) between two groups (brain tumor vs. stroke) by Mann-Whitney U test.
p<0.05,
p<0.01,
p<0.001 when comparing each scores of baseline and discharge within same group by Wilcoxonsigned rank test.
Fig. 2.Comparison of rehabilitation outcome for (A) efficiencies in brain tumor and stroke groups, and (B) efficiencies in malignant and benign brain tumor groups. There is no significant difference when efficiencies between two groups (brain tumor vs. stroke and malignant vs. benign brain tumor) are compared by Mann-Whitney U test. The bold line in the box represents the median value. The interquartile range box represents the middle 50% of each data. The whisker represents ranges for the bottom 25% and the top 25%, excluding outliers. FMA, Fugl-Meyer Assessment; BBS, Berg Balance Scale; K-MBI, Korean version of Modified Barthel Index; K-MMSE, Korean Mini-Mental State Examination; IQ, intelligence quotient.
Multivariate linear regression analysis between initial state and rehabilitation outcomes in brain tumor patients
| Variable | Outcome | Predictor | Adjusted R2 | p-value |
|---|---|---|---|---|
| Brain tumor group | Change of FMA | Baseline FMA | 0.032 | <0.001[ |
| Change of BBS | Baseline BBS | 0.084 | 0.041[ | |
| Change of MBI | Baseline K-MBI | 0.354 | 0.034[ | |
| Change of K-MMSE | Baseline K-MMSE | 0.354 | <0.001[ | |
| Baseline IQ | 0.200 | 0.004[ | ||
| Change of IQ | Baseline K-MMSE | 0.181 | 0.006[ | |
| Baseline IQ | 0.402 | <0.001[ | ||
| Benign tumor subgroup | Change of FMA | Baseline K-MMSE | 0.263 | 0.010[ |
| Baseline IQ | 0.456 | <0.001[ | ||
| Change of BBS | Baseline BBS | 0.150 | 0.047[ | |
| Change of K-MBI | Baseline K-MBI | 0.219 | 0.019[ | |
| Change of K-MMSE | Baseline K-MMSE | 0.918 | 0.005[ | |
| Baseline IQ | 0.294 | 0.007[ | ||
| Change of IQ | Baseline K-MBI | 0.344 | 0.003[ | |
| Malignant tumor subgroup | Change of BBS | Baseline FMA | 0.252 | 0.039[ |
| Change of K-MBI | Baseline K-MBI | 0.185 | 0.029[ | |
| Change of K-MMSE | Baseline K-MBI | 0.373 | 0.012[ | |
| Baseline K-MMSE | 0.337 | 0.017[ | ||
| Change of IQ | Baseline IQ | 0.256 | 0.038[ |
FMA, Fugl-Meyer Assessment; BBS, Berg Balance Scale; K-MBI, Korean version of Modified Barthel Index; K-MMSE, Korean Mini-Mental State Examination; IQ, intelligence quotient.
p<0.05,
p<0.01,
p<0.001 when comparing each score of baselines and change within the same group by multivariate linear regression analysis.
Fig. 3.Survival estimates in patients with brain tumor. The survival rate was analyzed using the Kaplan-Meier survival curve. Cumulative survival probability is drawn according to different pathology (benign vs. malignant) in brain tumor since brain tumor operation (A) and initiation of rehabilitation therapy (B). (A) Since brain tumor operation, overall mean survival was 93.6 months. It was 116.6 months and 52.9 months for benign and malignant tumors, respectively. (B) Since initiation of rehabilitation therapy, overall mean survival was 89.3 months. It was 112.6 months and 48.4 months for benign and malignant tumors, respectively.
Fig. 4.Results of telephone survey about current functions in patients with brain tumor. Opinion of family caregivers on current status of motor, activities of daily living (ADL), and cognitive function compared to the status on discharge in survived patients (3-point scale: improved, similar, and worsened) in benign brain tumor patients (n=15) (A) and malignant brain tumor patients (n=4) (B).
Fig. 5.Results of telephone survey about satisfaction in patients with brain tumor. (A) Brain tumor patients in total (n=26), (B) patients with malignant brain tumor (n=9), and (C) deceased patients with both benign and malignant brain tumor (n=7) are depicted.